All In Biotech

Drug Trial Radar · NCT00145327

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

Last checked: Nov 19, 2026Latest source record: Jun 28, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 2,456 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,456

Actual

Start

May 2005

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 68 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial. This extension study began after the 3-year core study ended. Baseline is the same as Year 3.

Conditions

  • Osteoporosis

Interventions

  • Zoledronic AcidDrug

    Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.

  • PlaceboDrug

    100 mL physiologic 0.9% normal saline for intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Bone Mineral Density (BMD) of Femoral Neck at Year 6 Relative to Year 3Time frame: Year 3 (Extension Baseline; Month 36 prior to the first treatment of the extension study) and Year 6 (Month 72; end of extension study)

Locations

31 sites in 2 countries. Site status is shown where the registry gives one.

  • Southern Arizona VA

    Tucson, Arizona

  • University of Arkansas for Medical Science

    Little Rock, Arkansas

  • Osteoporosis Medical Center

    Beverly Hills, California

  • Osteoporosis Prevention Center

    San Diego, California

  • Diablo Clinical Research, Inc

    Walnut Creek, California

  • Colorado Center for Bone Research

    Lakewood, Colorado

  • CRIA Research

    Fort Lauderdale, Florida

  • Radiant Research

    Stuart, Florida

  • Comprehensive Clinical Trials, LLC

    West Palm Beach, Florida

  • United Osteoporosis Centers (UOC)

    Gainesville, Georgia

  • Northwestern University Center for Clinical Research

    Chicago, Illinois

  • School of Medicine

    Indianapolis, Indiana

  • Medical Specialist Clinical Research Center

    Munster, Indiana

  • Heartland Research Associates, LLC

    Wichita, Kansas

  • Maine Center for Osteoporosis Research and Education

    Bangor, Maine

  • Osteoporosis Clinical Trial Center

    Hagerstown, Maryland

  • Clinical Pharmacology Study Groups

    Worcester, Massachusetts

  • Washington University Center for Clinical Studies

    St Louis, Missouri

  • New Mexico Clinical Research and Osteoporosis Center Inc

    Albuquerque, New Mexico

  • Winthrop U Hospital

    Mineola, New York

  • Odyssey Research Services/CCRC Internal Medical

    Fargo, North Dakota

  • University of Cincinnati Bone Health and Osteoporosis Center

    Cincinnati, Ohio

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Radiant Research

    Wyomissing, Pennsylvania

  • Rhode Island Hospital, Endocrinology Clinical Research Unit

    Providence, Rhode Island

  • University of Tennessee Health Science

    Memphis, Tennessee

  • McGuire Veterans Affairs Medical Center

    Richmond, Virginia

  • VA Commonwealth University

    Richmond, Virginia

  • Puget Sound Osteoporosis Center

    Seattle, Washington

  • Novartis

    Nuremberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.